AR029337A1 - Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv - Google Patents
Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hivInfo
- Publication number
- AR029337A1 AR029337A1 ARP000100901A ARP000100901A AR029337A1 AR 029337 A1 AR029337 A1 AR 029337A1 AR P000100901 A ARP000100901 A AR P000100901A AR P000100901 A ARP000100901 A AR P000100901A AR 029337 A1 AR029337 A1 AR 029337A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon alfa
- preparation
- against hiv
- pegilado
- hiv
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 3
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 3
- 229950000038 interferon alfa Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 2
- 229960000329 ribavirin Drugs 0.000 abstract 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 2
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 108010079944 Interferon-alpha2b Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 abstract 1
- 238000001050 pharmacotherapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Usos del interferon alfa, solo y en combinacion con una farmacoterapia contra el HIV-1 y la ribavirina para la preparacion de un medicamento para el tratamiento de pacientes que no han experimentado tratamientos y pacientes adultos y pediátricos infectados por el HIV-1 que han experimentado tratamientos así como pacientes coinfectados con HIV-1 y HCV, que comprende una cantidad terapéuticamente efectiva de interferon alfa pegilado, por ejemplo interferon alfa-2a o alfa-2b pegilado, como monoterapia o, preferentemente, en combinacion con una cantidad terapéuticamente efectiva de por lo menos una entre ribavirina, IL-2, IL-12 y pentafusida sola o en combinacion con una cantidad terapéuticamente efectiva de una farmacoterapia contra el HIV-1, por ejemplo HAART.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26038899A | 1999-03-02 | 1999-03-02 | |
| US26852199A | 1999-03-12 | 1999-03-12 | |
| US28835899A | 1999-04-08 | 1999-04-08 | |
| US45400499A | 1999-12-03 | 1999-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029337A1 true AR029337A1 (es) | 2003-06-25 |
Family
ID=27500674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100901A AR029337A1 (es) | 1999-03-02 | 2000-03-01 | Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1034790A3 (es) |
| JP (1) | JP2000256211A (es) |
| AR (1) | AR029337A1 (es) |
| AU (1) | AU3714800A (es) |
| CA (1) | CA2299893A1 (es) |
| CO (1) | CO5160259A1 (es) |
| PE (1) | PE20001548A1 (es) |
| WO (1) | WO2000051631A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525907A (ja) * | 2000-03-09 | 2003-09-02 | シェーリング コーポレイション | Ｈｉｖ免疫アジュバント治療 |
| RU2318004C2 (ru) | 2002-07-24 | 2008-02-27 | Ф.Хоффманн-Ля Рош Аг | Добавки в виде полиалкиленгликолевой кислоты |
| ATE519503T1 (de) * | 2007-09-14 | 2011-08-15 | Schering Corp | Verfahren zur behandlung von patienten mit hepatitis c |
| EP2455456A1 (en) | 2010-11-22 | 2012-05-23 | Institut Curie | Use of kinesin inhibitors in HIV infection treatment and a method for screening them |
| MX2017003546A (es) * | 2014-09-16 | 2017-08-14 | Ubi Ip Holdings | Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. |
| SG10202100268RA (en) | 2016-08-13 | 2021-02-25 | United Biopharma Inc | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| NZ276943A (en) * | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
-
2000
- 2000-03-01 AU AU37148/00A patent/AU3714800A/en not_active Abandoned
- 2000-03-01 PE PE2000000174A patent/PE20001548A1/es not_active Application Discontinuation
- 2000-03-01 CO CO00014824A patent/CO5160259A1/es unknown
- 2000-03-01 WO PCT/US2000/005361 patent/WO2000051631A2/en not_active Ceased
- 2000-03-01 AR ARP000100901A patent/AR029337A1/es unknown
- 2000-03-01 CA CA002299893A patent/CA2299893A1/en not_active Abandoned
- 2000-03-01 JP JP2000055695A patent/JP2000256211A/ja active Pending
- 2000-03-02 EP EP00301695A patent/EP1034790A3/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PE20001548A1 (es) | 2001-01-16 |
| CO5160259A1 (es) | 2002-05-30 |
| EP1034790A3 (en) | 2000-12-13 |
| WO2000051631A3 (en) | 2001-01-18 |
| CA2299893A1 (en) | 2000-09-02 |
| JP2000256211A (ja) | 2000-09-19 |
| AU3714800A (en) | 2000-09-21 |
| WO2000051631A2 (en) | 2000-09-08 |
| EP1034790A2 (en) | 2000-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023824A1 (es) | Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. | |
| PE119199A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica | |
| CO4940414A1 (es) | Terapia de interferones polietilenglicol modificados | |
| AR023541A1 (es) | Terapia de combinacion para vhc | |
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| AR019551A1 (es) | Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica | |
| UA29429C2 (uk) | Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини | |
| AR029337A1 (es) | Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv | |
| BR0108997A (pt) | Terapia imune adjuvante para hiv | |
| AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| ES2052922T3 (es) | Nucleosidos terapeuticos. | |
| WO2004033479A3 (en) | Retroyclins: antiviral and antimicrobial peptides | |
| ECSP003373A (es) | Terapia contra el hiv | |
| AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
| BRPI0409711A (pt) | tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina | |
| ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
| AR023398A1 (es) | Terapia para melanomas | |
| BR9812466A (pt) | Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica | |
| PT1150981E (pt) | Composto nucleosidico terapeutico | |
| AU8353601A (en) | Treatment of hepatitis c with thymosin, interferon and ribavirin | |
| DE69130571D1 (de) | Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen | |
| Rutherford | Increasing the number of drugs in antiretroviral therapy may improve survival in people with HIV infection | |
| YU17703A (sh) | Nova farmaceutska kompozicija za primenu na koži |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |